Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Peripheral T-Cell Lymphoma

Conditions

Peripheral T-Cell Lymphoma

Trial Timeline

Jul 1, 2008 → Jun 23, 2016

NCT ID

NCT00632827

About Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox

Gemcitabine + Navelbine + Doxorubicin Hydrochloride Liposome Injection + Granulocyte-colony stimulating factor (G-CSF) + Pegfilgrastim + Cyclophosphamide + Vincristine + Leucovorin + Methotrexate + Doxorubicin Hydrochloride + Cytarabine + Etoposide + Carmustine + Denileukin diftitox is a phase 2 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00632827. Target conditions include Peripheral T-Cell Lymphoma.

What happened to similar drugs?

20 of 20 similar drugs in Peripheral T-Cell Lymphoma were approved

Approved (20) Terminated (4) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved

✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved

✅Ticagrelor + clopidogrelAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00632827	Phase 2	Terminated	Jul 1, 2008	Jun 23, 2016	Peripheral T-Cell Lymphoma

Competing Products

20 competing products in Peripheral T-Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	18
LY3857210 + Placebo	Eli Lilly	Phase 2	35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
YHD1119 + Lyrica	Yuhan	Phase 1	29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tid	Yuhan	Approved	43
YHD1119 + Lyrica	Yuhan	Phase 1	29
YHD1119 + Lyrica	Yuhan	Phase 3	40
YHD1119 300mg + YHD1119 300mg	Yuhan	Phase 1	29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
edoxaban + Clopidogrel + Aspirin	Daiichi Sankyo	Phase 2	35
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
Qutenza	Astellas Pharma	Pre-clinical	26
QUTENZA + Lidocaine + Tramadol	Astellas Pharma	Approved	43
Qutenza exposure	Astellas Pharma	Pre-clinical	26
QUTENZA	Astellas Pharma	Phase 3	40
Qutenza + Pregabalin	Astellas Pharma	Approved	43